Cargando…
An Immunobridging Study to Evaluate the Neutralizing Antibody Titer in Adults Immunized with Two Doses of Either ChAdOx1-nCov-19 (AstraZeneca) or MVC-COV1901
Rapid development and deployment of vaccines is crucial to control the continuously evolving COVID-19 pandemic. The placebo-controlled phase 3 efficacy trial is still the standard for authorizing vaccines in the majority of the world. However, due to a lack of eligible participants in parts of the w...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9146038/ https://www.ncbi.nlm.nih.gov/pubmed/35632411 http://dx.doi.org/10.3390/vaccines10050655 |
_version_ | 1784716462195212288 |
---|---|
author | Estrada, Josue Antonio Cheng, Chien-Yu Ku, Shin-Yen Hu, Hui-Chun Yeh, Hsiu-Wen Lin, Yi-Chun Chen, Cheng-Pin Cheng, Shu-Hsing Janssen, Robert Lin, I-Feng |
author_facet | Estrada, Josue Antonio Cheng, Chien-Yu Ku, Shin-Yen Hu, Hui-Chun Yeh, Hsiu-Wen Lin, Yi-Chun Chen, Cheng-Pin Cheng, Shu-Hsing Janssen, Robert Lin, I-Feng |
author_sort | Estrada, Josue Antonio |
collection | PubMed |
description | Rapid development and deployment of vaccines is crucial to control the continuously evolving COVID-19 pandemic. The placebo-controlled phase 3 efficacy trial is still the standard for authorizing vaccines in the majority of the world. However, due to a lack of eligible participants in parts of the world, this has not always been feasible. Recently, the Taiwan Food and Drug Administration, following the consensus of the International Coalition of Medicines Regulatory Authorities (ICMRA), adopted the use of immunobridging studies as acceptable for authorizing COVID-19 vaccines in lieu of efficacy data. Here, we describe a study in which our candidate vaccine, MVC-COV1901, an adjuvanted protein subunit vaccine, has been granted emergency use authorization (EUA) in Taiwan based on a noninferiority immunobridging study. Immunogenicity results from the per protocol immunogenicity (PPI) subset (n = 903) from the MVC-COV1901 phase 2 trial were compared with results from 200 subjects who had received an adenovirus vector vaccine, AstraZeneca ChAdOx nCOV-19 (AZD1222), in a separate study. The lower bound of the 95% confidence interval (CI) of the geometric mean titer (GMT) ratio comparing MVC-COV1901 to AZD1222 was 3.4. The lower bound of the 95% CI of the sero-response rate was 95.5%. Both the GMT ratio and sero-response rate exceeded the criteria established by the Taiwan regulatory authority, leading to EUA approval of MVC-COV1901 in Taiwan. |
format | Online Article Text |
id | pubmed-9146038 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-91460382022-05-29 An Immunobridging Study to Evaluate the Neutralizing Antibody Titer in Adults Immunized with Two Doses of Either ChAdOx1-nCov-19 (AstraZeneca) or MVC-COV1901 Estrada, Josue Antonio Cheng, Chien-Yu Ku, Shin-Yen Hu, Hui-Chun Yeh, Hsiu-Wen Lin, Yi-Chun Chen, Cheng-Pin Cheng, Shu-Hsing Janssen, Robert Lin, I-Feng Vaccines (Basel) Article Rapid development and deployment of vaccines is crucial to control the continuously evolving COVID-19 pandemic. The placebo-controlled phase 3 efficacy trial is still the standard for authorizing vaccines in the majority of the world. However, due to a lack of eligible participants in parts of the world, this has not always been feasible. Recently, the Taiwan Food and Drug Administration, following the consensus of the International Coalition of Medicines Regulatory Authorities (ICMRA), adopted the use of immunobridging studies as acceptable for authorizing COVID-19 vaccines in lieu of efficacy data. Here, we describe a study in which our candidate vaccine, MVC-COV1901, an adjuvanted protein subunit vaccine, has been granted emergency use authorization (EUA) in Taiwan based on a noninferiority immunobridging study. Immunogenicity results from the per protocol immunogenicity (PPI) subset (n = 903) from the MVC-COV1901 phase 2 trial were compared with results from 200 subjects who had received an adenovirus vector vaccine, AstraZeneca ChAdOx nCOV-19 (AZD1222), in a separate study. The lower bound of the 95% confidence interval (CI) of the geometric mean titer (GMT) ratio comparing MVC-COV1901 to AZD1222 was 3.4. The lower bound of the 95% CI of the sero-response rate was 95.5%. Both the GMT ratio and sero-response rate exceeded the criteria established by the Taiwan regulatory authority, leading to EUA approval of MVC-COV1901 in Taiwan. MDPI 2022-04-21 /pmc/articles/PMC9146038/ /pubmed/35632411 http://dx.doi.org/10.3390/vaccines10050655 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Estrada, Josue Antonio Cheng, Chien-Yu Ku, Shin-Yen Hu, Hui-Chun Yeh, Hsiu-Wen Lin, Yi-Chun Chen, Cheng-Pin Cheng, Shu-Hsing Janssen, Robert Lin, I-Feng An Immunobridging Study to Evaluate the Neutralizing Antibody Titer in Adults Immunized with Two Doses of Either ChAdOx1-nCov-19 (AstraZeneca) or MVC-COV1901 |
title | An Immunobridging Study to Evaluate the Neutralizing Antibody Titer in Adults Immunized with Two Doses of Either ChAdOx1-nCov-19 (AstraZeneca) or MVC-COV1901 |
title_full | An Immunobridging Study to Evaluate the Neutralizing Antibody Titer in Adults Immunized with Two Doses of Either ChAdOx1-nCov-19 (AstraZeneca) or MVC-COV1901 |
title_fullStr | An Immunobridging Study to Evaluate the Neutralizing Antibody Titer in Adults Immunized with Two Doses of Either ChAdOx1-nCov-19 (AstraZeneca) or MVC-COV1901 |
title_full_unstemmed | An Immunobridging Study to Evaluate the Neutralizing Antibody Titer in Adults Immunized with Two Doses of Either ChAdOx1-nCov-19 (AstraZeneca) or MVC-COV1901 |
title_short | An Immunobridging Study to Evaluate the Neutralizing Antibody Titer in Adults Immunized with Two Doses of Either ChAdOx1-nCov-19 (AstraZeneca) or MVC-COV1901 |
title_sort | immunobridging study to evaluate the neutralizing antibody titer in adults immunized with two doses of either chadox1-ncov-19 (astrazeneca) or mvc-cov1901 |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9146038/ https://www.ncbi.nlm.nih.gov/pubmed/35632411 http://dx.doi.org/10.3390/vaccines10050655 |
work_keys_str_mv | AT estradajosueantonio animmunobridgingstudytoevaluatetheneutralizingantibodytiterinadultsimmunizedwithtwodosesofeitherchadox1ncov19astrazenecaormvccov1901 AT chengchienyu animmunobridgingstudytoevaluatetheneutralizingantibodytiterinadultsimmunizedwithtwodosesofeitherchadox1ncov19astrazenecaormvccov1901 AT kushinyen animmunobridgingstudytoevaluatetheneutralizingantibodytiterinadultsimmunizedwithtwodosesofeitherchadox1ncov19astrazenecaormvccov1901 AT huhuichun animmunobridgingstudytoevaluatetheneutralizingantibodytiterinadultsimmunizedwithtwodosesofeitherchadox1ncov19astrazenecaormvccov1901 AT yehhsiuwen animmunobridgingstudytoevaluatetheneutralizingantibodytiterinadultsimmunizedwithtwodosesofeitherchadox1ncov19astrazenecaormvccov1901 AT linyichun animmunobridgingstudytoevaluatetheneutralizingantibodytiterinadultsimmunizedwithtwodosesofeitherchadox1ncov19astrazenecaormvccov1901 AT chenchengpin animmunobridgingstudytoevaluatetheneutralizingantibodytiterinadultsimmunizedwithtwodosesofeitherchadox1ncov19astrazenecaormvccov1901 AT chengshuhsing animmunobridgingstudytoevaluatetheneutralizingantibodytiterinadultsimmunizedwithtwodosesofeitherchadox1ncov19astrazenecaormvccov1901 AT janssenrobert animmunobridgingstudytoevaluatetheneutralizingantibodytiterinadultsimmunizedwithtwodosesofeitherchadox1ncov19astrazenecaormvccov1901 AT linifeng animmunobridgingstudytoevaluatetheneutralizingantibodytiterinadultsimmunizedwithtwodosesofeitherchadox1ncov19astrazenecaormvccov1901 AT estradajosueantonio immunobridgingstudytoevaluatetheneutralizingantibodytiterinadultsimmunizedwithtwodosesofeitherchadox1ncov19astrazenecaormvccov1901 AT chengchienyu immunobridgingstudytoevaluatetheneutralizingantibodytiterinadultsimmunizedwithtwodosesofeitherchadox1ncov19astrazenecaormvccov1901 AT kushinyen immunobridgingstudytoevaluatetheneutralizingantibodytiterinadultsimmunizedwithtwodosesofeitherchadox1ncov19astrazenecaormvccov1901 AT huhuichun immunobridgingstudytoevaluatetheneutralizingantibodytiterinadultsimmunizedwithtwodosesofeitherchadox1ncov19astrazenecaormvccov1901 AT yehhsiuwen immunobridgingstudytoevaluatetheneutralizingantibodytiterinadultsimmunizedwithtwodosesofeitherchadox1ncov19astrazenecaormvccov1901 AT linyichun immunobridgingstudytoevaluatetheneutralizingantibodytiterinadultsimmunizedwithtwodosesofeitherchadox1ncov19astrazenecaormvccov1901 AT chenchengpin immunobridgingstudytoevaluatetheneutralizingantibodytiterinadultsimmunizedwithtwodosesofeitherchadox1ncov19astrazenecaormvccov1901 AT chengshuhsing immunobridgingstudytoevaluatetheneutralizingantibodytiterinadultsimmunizedwithtwodosesofeitherchadox1ncov19astrazenecaormvccov1901 AT janssenrobert immunobridgingstudytoevaluatetheneutralizingantibodytiterinadultsimmunizedwithtwodosesofeitherchadox1ncov19astrazenecaormvccov1901 AT linifeng immunobridgingstudytoevaluatetheneutralizingantibodytiterinadultsimmunizedwithtwodosesofeitherchadox1ncov19astrazenecaormvccov1901 |